Welcome, Guest. Please login or register.
May 27, 2019, 12:07:52 am

Login with username, password and session length


Members
  • Total Members: 6097
  • Latest: Sage
Stats
  • Total Posts: 54085
  • Total Topics: 4554
  • Online Today: 77
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 75
Total: 75

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Liver Fat Isn’t the True Culprit Behind NASH-Related Disease Progression  (Read 2461 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 599
    • Hep Mag
Liver fat content does not drive disease progression among people with non-alcoholic steatohepatitis (NASH); rather, fibrosis, or scarring of the organ, is the culprit, MedPage Today reports. Researchers reached this conclusion during otherwise failed placebo-controlled trials of a treatment for NASH, the cloned antibody simtuzumab.

Between the two trials, investigators enrolled 477 people with NASH, including 219 people with bridging fibrosis and 258 with cirrhosis, to receive a planned 240 weeks of simtuzumab.

At the 96-week mark of the trials, the treatment showed no efficacy and the studies were discontinued.

Read more...
https://www.hepmag.com/article/liver-fat-true-culprit-behind-nashrelated-disease-progression

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.